Source: Annual Congress 2012 - Basic and translational studies in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Villar-Álvarez, A. García-Fernández, A. Ferrarini, J. Gómez-Seco, M. Rodríguez-Guzmán, J. Ruiz-Cabello, C. Barbas-Arribas, G. Peces-Barba (Madrid, Spain). Metabolomic fingerprinting in the identification of biomarkers in COPD patients. Eur Respir J 2012; 40: Suppl. 56, 1436

Member's Comments

No comment yet.

Related content which might interest you: Mass spectrometry proteomic biomarkers identify acute COPD exacerbations Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Metabolomic profiling differences among asthma, COPD and healthy controls: a LC-MS-based metabolomics analysis Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Phenotypic fingerprinting of disease through biomarker profiling Source: Annual Congress 2010 - New tools for the trade: novel emerging technologies to assess lung development and disease Year: 2010 Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Proteomic analysis of sputum from adults with cystic fibrosis and COPD: identification of potential biomarkers for disease monitoring Source: Eur Respir J 2006; 28: Suppl. 50, 152s Year: 2006 Metabolomics identifies biomarkers of exacerbations in smokers with and without COPD Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases Year: 2020 A NMR-based metabolomics approach to the assessment of inhaled pharmacotherapy in patients with COPD Source: International Congress 2019 – Basic research of airway diseases Year: 2019 Metabolomic profiling of clinical sputum samples reveals novel biomarkers for the early identification of lung cancer patients Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Proteomic derived biomarkers for COPD are present in induced sputum Source: Eur Respir J 2005; 26: Suppl. 49, 439s Year: 2005 Metabolomic fingerprinting of serum samples based on direct infusion mass spectrometry for lung cancer diagnosis Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 Application of omics technologies to the identification of biomarkers for COPD Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 Preliminary proteomics analysis for sepsis biomarkers with iTRAQ labeling and LC-MS/MS Source: Annual Congress 2013 –Research questions on how viruses affect the respiratory system Year: 2013 Role of biomarkers in the assessment and phenotyping asthma and COPD Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Microarray profiling of COPD patients versus non-COPD smokers reveals possible disease biomarkers Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 New approaches to tuberculosis diagnosis through the study of metabolomic profile in urine Source: Annual Congress 2013 –Tuberculosis diagnosis Year: 2013 A liquid chromatography MS/MS metabolomics study of COPD patients Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Altered serum metabolomics in COPD: analysis of the SPIROMICS cohort Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 A comparative proteomic profiling of the human erythrocyte membrane in COPD patients Source: Annual Congress 2009 - New results in molecular pathology and functional genomics of non-neoplastic lung diseases Year: 2009 Discrimination of sepsis metabolic profiles revealed by LC/MS-MS based metabonomics approach Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013